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Background: Treponemal tests for detecting syphilis should be sufﬁciently sensitive and speciﬁc, especially when
used as the ﬁrst-line method in reverse-algorithm testing. We compared the Siemens ADVIA Centaur® Syphilis
assay to 2 other commercial assays in use by the Star-MDC laboratory to evaluate its performance and usability.
Methods: Agreement between the Siemens ADVIA Centaur Syphilis assay, Siemens IMMULITE® 2000 Syphilis
Screen, and Biokit bioelisa Syphilis 3.0 assay was evaluated using 1251 patient samples (50 from known posi-
tives, 701 from patients referred for syphilis testing, and 500 from pregnant women). Reactive samples (i.e., re-
active according to at least two of the three treponemal methods)were further evaluated usingWestern blot IgG
and IgM, and Venereal Disease Research Laboratory (VDRL) testing.
Results: Overall, positive and negative agreement was 100% between the Centaur and IMMULITE assays. In this
study, overall agreement was 99.92% between either of the Siemens assays and the Biokit assay; positive agree-
ment was 99%, and negative agreement was 100%. Overall, 0.88% (11/1251) of the samples were interpreted as
positive/reactive based on the combined positive results by the ADVIA Centaur, IMMULITE 2000, and bioelisa as-
says; a positive Euroline anti-Treponema pallidum IgM blot; and a VDRL result of ≥1:8. In this study, no false-
reactive samples were identiﬁed using this method.
Conclusion: The Centaur Syphilis assay performance is comparable to the other 2 commercial assays.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Syphilis is a sexually transmitted disease caused by the bacterium
Treponema pallidum subspecies pallidum. This disease is also passed
from infected pregnant women to their offspring in utero. Syphilis can
be classiﬁed into three infectious stages (primary, secondary, and
early latent) and 2 noninfectious disease stages (late latent and tertiary)
[1–3]. Because T. pallidum is capable of infecting awide variety of tissues
[1–4], the disease canmimic a variety of conditions in its clinical presen-
tation. Thus, laboratory analysis in combination with clinical presenta-
tion plays an important role in the diagnosis of syphilis.
There are 2 types of serological tests for syphilis: nontreponemal and
treponemal tests. Nontreponemal tests are not speciﬁc for treponemal
antigen. Instead, these tests detect antibodies to cardiolipin, which is a
component of both the treponemalmembrane and the eukaryoticmito-
chondrial membrane. Reactivity to mitochondrial cardiolipin stemsatory; RPR, rapid plasma reagin;
Treponema pallidum particle ag-
bsorbed test; Tp15, T. pallidum
ium ester; RLUs, relative light
1 818 346 0558.
.
. This is an open access article underfrom host cellular debris, whichmay result from the immunological re-
sponse to treponemal infection but can also arise due to nonrelated cel-
lular damage. Two common nontreponemal methods in standard use
are the Venereal Disease Research Laboratory (VDRL) test and the
rapid plasma reagin (RPR) card test. In contrast, treponemal tests detect
speciﬁc treponemal antibodies. These include the Treponema pallidum
hemagglutination assay (TPHA), Treponema pallidum particle agglutina-
tion assay (TPPA), ﬂuorescent treponemal antibody-absorbed test (FTA-
ABS), and most enzyme immunoassays (using antibodies created
against native and/or recombinant antigens) [2,4].
Two primary approaches to testing are currently in use [1,3,5]. In the
traditional testing algorithm, a nontreponemal test is performed ﬁrst. If
reactive, it is followedby treponemal testing. Nontreponemal testing re-
quires manual pipetting, which can be very time-consuming and labor-
intensive; it is alsomore likely to generate a large number of samples re-
quiring follow-up testing due to nonspeciﬁc detection of cardiolipin.
Another approach that is becoming increasingly popular is to perform
a treponemal test ﬁrst and then, if reactive, perform a nontreponemal
test to conﬁrm the results and establish state of infection (acute vs. re-
mote). The popularity of this method—termed reverse algorithm—con-
tinues to grow for two primary reasons: Increasing syphilis infection
rates in many parts of the world, including the U.S. and Europe
(where 12 million new infections are anticipated annually), are drivingthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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addition, test volume is increasing because many countries are now re-
quiring screening of all pregnant women to preventmaternal transmis-
sion. Popularity of the reverse-algorithm method has grown because it
can be conducted more efﬁciently using fully automated treponemal
tests. Not only are such tests less time-consuming and less labor-
intensive, but they typically also have higher sensitivity than
nontreponemal tests in the primary and latent disease stages [1–5]. Re-
gardless of the algorithm applied, both treponemal testing and
nontreponemal testing are required to conﬁrm a syphilis infection and
determine its stage.
2. Materials and methods
2.1. Patient samples
A total of 1251 patient samples were tested for the presence of
T. pallidum antibodies at Star-MDC (Rotterdam, The Netherlands). All
samples were drawn sequentially at the Star-MDC center as requested
by a treating physician. Fresh samples were taken from 500 pregnant
women in the course of regular obstetric care, and 701 samples were
drawn from at-risk individuals suspicious for syphilis; these samples
were either tested immediately or stored between 2 and 7 h at 4 °C
until tested. The other 50 samples were remnant samples (stored at
−25 °C) from known positives previously diagnosed and treated for
syphilis at our institute. Per Star-MDC's policy, all blood samples used
for studies were fully de-identiﬁed and used with patient consent.
2.2. Testing protocol (comparison of treponemal assay methods)
All sampleswere tested in duplicate using each of the three trepone-
mal assays. Samples that were negative by all 3 assays were classiﬁed as
negative. Samples that were positive according to 2 of the 3 assays or all
3 were considered positive. Our goals were to evaluate agreement be-
tween the ADVIA Centaur Syphilis assay and the other 2 assays and to
determine its usability as a primary treponemal testing method. For
these reasons, our protocol called for retesting all results thatwere reac-
tive according to the Centaur Syphilis assay, even if samples were non-
reactive according to both of the other two assays. However, no samples
of this type were identiﬁed.
Presumed positive samples were then tested with the Euroline IgM
and IgG assays (Medizinische Labordiagnostika AG) and the VDRL
assay to establish the status of the infection. Active syphilis infections
were conﬁrmed on the basis of positive status assigned using the 3 trep-
onemal assays in conjunction with the nontreponemal testing, i.e., aFig. 1. The classiﬁcapositive Euroline anti-Treponema pallidum IgM and/or IgG blot and a
VDRL titer of ≥1:8 (Fig. 1).
2.3. Statistical analysis
TheADVIACentaur assaywas compared to each of the other 2 assays
in terms of statistical positive and negative agreement. Agreement was
chosen as the appropriate statistical method since none of the predicate
tests—including the conﬁrmatory Western blot and nontreponemal
tests used in the study—constitute a deﬁnitive reference standard (in
fact, no deﬁnitive reference standard has been deﬁned for syphilis test-
ing) [6]. Additionally, although positive agreement and negative agree-
ment are analogous to sensitivity and speciﬁcity, the use of agreement
clariﬁes that the comparison is made relative to an existing assay, and
not to a clinical diagnosis [2,7–9]. Agreement was calculated along
with the 95% conﬁdence intervals [9]. Although overall agreement is re-
ported, it is not as statistically sound as positive and negative agree-
ment; we have reported it in this document for the sake of
completeness.
3. Results
Using the algorithm described in the methods, we determined that
100 of the 1251 sampleswere treponemal antigen-positive. This includ-
ed 50 newly identiﬁed syphilis-positive sera (beyond the 50 already-
known positive sera). The large number of newly identiﬁed positives
might seem unlikely, given that it indicates prevalence far greater
than that of the general population. However, it is not unexpected, as
701 sera were taken from individuals practicing high-risk behavior
and who were tested for a variety of sexually transmitted diseases. Of
these 50 additional samples, 2 cases represented active syphilis, while
the other 48 represented remote infections (3 ofwhichwere frompreg-
nant women). In total, among the 100 treponemal antigen-positive
samples, we identiﬁed 11 cases of active syphilis and 89 remote cases
(Table 1).
Agreement between each of the 3 treponemal assays in this study
was ≥99%. Positive agreement reﬂects the number of sera that were
positive according to each assay, while negative agreement reﬂects
the number of sera that were negative according to each assay. Total
agreement is the combined number of positive and negative results
for each assay (Table 2).
A single sample yielded discordant results between the Siemens and
Biokit assays. This samplewas negative according to both the IMMULITE
2000 and ADVIA Centaur assays but positive by the Biokit bioelisa assay.
Upon further testing, this sample was also negative according to bothtion algorithm.
Table 1
Status of treponemal-positive samples according to the application of immunoassay, VDRL
quantitative, and Euroline IgM and IgG assays combined results.
No. samples VDRL titer IgM IgG
Active syphilis 3 1:8 + +
5 1:16 + +
1 1:32 + +
2 1:64 + +
Remote infection 8 1:1 − +
6 1:2 − +
75⁎ − − +
⁎ One IgM-negative/IgG-positive sample was missing VDRL information. This sample
was also positive according to the Centaur, IMMULITE, and ELISA assays, andwas therefore
included as a remote infection.
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that this sample is truly negative (i.e., conﬁrming the Centaur and
IMMULITE 2000 assays is likely correctly reporting negative results in
the absence of infection). This suggests that the two Siemens assays
might be potentially less likely to generate false-positive results than
the Biokit assay; however, we recognize that such results will likely
vary between studies and populations.
4. Discussion
When new tests become available, their accuracy can best be
established by direct comparison of results to a reference standard.
Such a standard could be an individual method of proven and accepted
accuracy or an established diagnostic algorithm [7]. However, in the
case of syphilis testing, no single test or deﬁnitive reference standard
is available for every stage of the disease [2]. Only dark ﬁeldmicroscopy
provides visual conﬁrmation of T. pallidum infection, but applicability of
this method is limited to acute infection in which open lesions can be
cultured. Thus, syphilis diagnosis relies predominantly on serological
testing, requiring results from both nontreponemal and treponemal
methods. Since these two types of tests target different biomarkers, sta-
tistical accuracy of new treponemal tests canbe evaluated by comparing
agreement of results to already-established treponemal methods [7].
Such analysis is also useful to determine if a new test may be used in
place of, or alongside of, a test currently in use.
At our institution, we used our own variant of a reverse-algorithm
protocol to determine statistical positive, negative, and total agreement
between the treponemal Centaur Syphilis assay and each of the 2 other
treponemal assays in use by our laboratory: the IMMULITE 2000 Syph-
ilis Screen and the Biokit bioelisa assay. All 3 of these tests areTable 2
Comparison of the syphilis assays evaluated in this study.
IMMULITE
Positive Negative
Centaur Positive 100 0
Negative 0 1151
# Agreed/total Agreement 95% CI
Overall agreement 1251/1251 100% 99.7–100%
Positive agreement 100/100 100% 96.4–100%
Negative agreement 1151/1151 100% 99.7–100%
Biokit bioelisa
Positive Negative
Siemens (IMMULITE or Centaur) Positive 100 0
Negative 1 1150
# Agreed/total Agreement 95% CI
Overall agreement 1250/1251 99.92% 99.6–100%
Positive agreement 100/101 99% 96.4–100%
Negative agreement 1150/1150 100% 99.7–100%immunoassays employing recombinant T. pallidum surface antigens to
detect total antibody in serum. Results demonstrated 100% positive,
negative, and total agreement between the 2 Siemens assays. However,
it should be noted that they are characteristic of performance deter-
mined by an independent laboratory and do not represent the
manufacturer's claims (results may vary from laboratory to laboratory
and can be affected by syphilis prevalence in the population examined).
The results also demonstrated 99% positive agreement, 100% negative
agreement, and 99.92% total agreement between each of the Siemens
assays and the Biokit assay. This high level of agreement may be due
in part to the detection of antibodies to Tp17 antigens by all 3 trepone-
mal assays.
While the intent of this study was only to establish comparable per-
formance andusability of theADVIA Centaur assay for our laboratory, an
interesting secondary observation indicates results that are inconsistent
with two earlier reports by the CDC addressing the accuracy of primary
treponemal testing [10,11]. In both CDC reports, when treponemal EIA
assays were applied as the initial syphilis test, over 50% of the positive
results were found to be negative using RPR. In the 2008 study, 17% of
the EIA-positive/RPR-negative results could not be conﬁrmed using a
second treponemal method (FTA-ABS or TPPA); similar results were re-
ported by Binnicker et al. in amuch smaller study [1]. In the 2011 report,
up to 60% of the treponemal-positive/nontreponemal-negative (EIA+/
RPR−) samples could not be conﬁrmed using TPPA in low-prevalence
populations, and up to 18.6% could not be conﬁrmed in high-
prevalence populations. On the basis of these studies, the CDC suggests
that treponemal-speciﬁc EIAs (or at least the three used in their study)
can generate a high rate of false-positive results when used for primary
analysis and recommends conﬁrming EIA+/RPR− results using the
TPPA method.
In contrast, in this study it appears that none of the treponemal-
positive samples/VDRL-negative samples were falsely reactive, and all
of these samples represent successfully treated past infections. We be-
lieve that we did not see false-positives because the EIA results were
conﬁrmed using multiple EIA assays before proceeding to
nontreponemal testing. This suggests that the number of false-positive
results in the ﬁnal conﬁrmatory step might be reduced by modifying
the current reverse algorithm (i.e., treponemal testing followed by
nontreponemal testing, and then conﬁrmation with a second trepone-
mal assay if initial and nontreponemal testing results are discordant)
to the proposed algorithm in which two different nontreponemal
methods are used initially to conﬁrm treponemal positivity before de-
termining active vs. past infection using a nontreponemal assay. Be-
cause treponemal-positive/nontreponemal-positive results would
normally not require a second conﬁrmatory treponemal test, our algo-
rithm will likely increase the total cost of testing. However, it would
streamline the laboratory testing process by further reducing the num-
ber of manual nontreponemal tests performed. At the very least, this
study indicates that a second treponemal EIA should provide conﬁrma-
tory results comparable to what may be achieved using TPPA. In fact,
neither the TPPA nor the TPHA methods are used now by most labora-
tories in the Netherlands (especially large laboratories), as they are
manual and thus more time-consuming and prone to error when per-
formed in large volume.
Use of a second EIA rather than TPPA is also potentially supported by
a recent study by Binnicker et al. In this study, the commercial trepone-
mal EIA assays evaluated performed comparably to TPPA, suggesting
that a second or third treponemal EIA can serve as an acceptable conﬁr-
matory tool as long as its sensitivity and speciﬁcity are comparable to
that of TPPA [12]. A study conducted for the WHO by Ebel et al. deter-
mined that the Biokit bioelisa assay has 99.5% sensitivity and 99.4%
speciﬁcity [6]. Although this test was compared to FTA-ABS rather
than TPPA, sensitivity and speciﬁcity are comparable to the seven assays
evaluated by Binnicker et al. (sensitivity was 98.9% for TPPA and ranged
from 96.8% to 100% for the other six assays; speciﬁcity was 97.6% for
TPPA and ranged from 94.3% to 99% for the other six assays) [12]. In a
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alongside TPPA (sensitivity = 99.1, 95% CI: 85.1–100%; speciﬁcity =
100%) and several other treponemal methods, it was found to have
98.2% sensitivity (95% CI: 93.8–99.8%) and 100% speciﬁcity [13]. The
N99% agreement of the Siemens assays with the Biokit assay indicates
that sensitivity and speciﬁcity are likely comparable. We therefore feel
that the use of the three treponemal assays in this study constitutes suf-
ﬁcient evidence for conﬁrmation of reactivity.
5. Limitations of the study
The primary limitation of this study was that we did not include
well-characterized samples from individuals with diseases known to
potentially cross-react with treponemal assays to yield a false-positive
result (such as a variety of viral and autoimmune disorders). We also
did not include samples from patients known to have problematic pre-
sentations, such as very early syphilis, neurosyphilis, coinfection with
HIV, or congenital syphilis [2,3]. We did, however, include a large popu-
lation of pregnantwomen. Although nontreponemal testing of pregnant
women is associated with false-positive results, Larsen et al. point out
that treponemal tests can also yield false-positives, although to a lesser
extent [3,14]. Regardless, of the 500 pregnantwomen tested for syphilis
by our laboratory, only three were positive according to the treponemal
tests; using nontreponemal andWestern blotmethods, all of thesewere
conﬁrmed to have been the result of a past infection. Since pregnant
women constitute a major portion of Star-MDC's routine syphilis-
testing population, it wasmore important for us to establish the perfor-
mance of the ADVIA Centaur test during pregnancy than for other po-
tentially interfering disease states.References
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